Skip to main content
JAGX
NASDAQ Life Sciences

克罗非勒治疗犬类腹泻试验取得统计学显著性，接近获得全面的FDA批准

feedReported by Access Newswire
Sentiment info
Positive
Importance info
7
Price
$0.228
Mkt Cap
$3.138M
52W Low
$0.24
52W High
$13.25
Market data snapshot near publication time

summarizeSummary

Jaguar Health宣布其克罗非勒（Canalevia-CA1）治疗化疗引起的犬类腹泻的有效性试验取得了统计学显著性的顶线结果。该试验显示，经过治疗的狗在三天后平均每日粪便恢复正常，83%的主人报告称该治疗方法是有效的。这些关键结果是获得Canalevia-CA1全面的FDA批准的关键一步，该产品目前仅获得条件性批准。这种积极的产品开发为Jaguar Health提供了一个罕见的潜在催化剂，Jaguar Health最近面临着严重的财务困境、纳斯达克摘牌威胁，并实施了1比35的反向股票拆分以维持合规性。投资者现在将关注该公司提交的全面的监管批准以及其财务稳定性的进一步更新。

在该公告发布时，JAGX的交易价格为$0.23，交易所为NASDAQ，所属行业为Life Sciences，市值约为$313.8万。 52周交易区间为$0.24至$13.25。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Access Newswire。

show_chartPrice Chart

Share this article

Copied!

feed JAGX - Latest Insights

JAGX
Apr 30, 2026, 9:57 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Shareholders to Vote on Highly Dilutive $42.4M Financing Agreements Critical for Company Survival
Sentiment: Negative
View Wiseek Article
JAGX
Apr 29, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
Crofelemer Trial for Canine Diarrhea Achieves Statistical Significance, Nearing Full FDA Approval
Sentiment: Positive
View Wiseek Article
JAGX
Apr 27, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Jaguar Health Announces 1-for-35 Reverse Stock Split to Meet Nasdaq Listing Requirements
Sentiment: Negative
View Wiseek Article
JAGX
Apr 27, 2026, 9:00 AM EDT
Source: Access Newswire
Importance Score:
8
1-for-35 Reverse Stock Split Set for Jaguar Health as Nasdaq Grants Delisting Extension
Sentiment: Neutral
View Wiseek Article
JAGX
Apr 21, 2026, 8:22 AM EDT
Filing Type: PRE 14A
Importance Score:
10
Jaguar Health Seeks Shareholder Approval for Highly Dilutive $42.4M Financing to Address Capital Needs
Sentiment: Negative
View Wiseek Article
JAGX
Apr 21, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Stockholders Approve Massive Share Increase, Two Reverse Splits, and $10.8M Debt Conversion
Sentiment: Negative
View Wiseek Article
JAGX
Apr 13, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
Jaguar Health to Leverage AI, Pursue FDA Breakthrough Status for Crofelemer in Rare Disease
Sentiment: Positive
View Wiseek Article
JAGX
Apr 09, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Jaguar Health Believes It Has Regained Nasdaq Stockholders' Equity Compliance, Averting Delisting Threat
Sentiment: Positive
View Wiseek Article
JAGX
Apr 08, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
Jaguar Health Completes Pivotal Trial for Canine Diarrhea Drug Crofelemer, Eyes Full FDA Approval
Sentiment: Positive
View Wiseek Article
JAGX
Apr 07, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Jaguar Health Reports Deepening Losses and Nasdaq Delisting Threat Amidst 2025 Financials
Sentiment: Negative
View Wiseek Article